Speech by the President of the Republic on the sites of the Paris-Saclay Cancer Cluster and the Gustave Roussy Institute.

France Emmanuel Macron · President of France

4 February 2025 · World Cancer Day visit to the Paris-Saclay Cancer Cluster and Gustave Roussy Institute · Gustave Roussy Institute

Context
Macron addressed researchers, caregivers, and partners at the Gustave Roussy Institute on World Cancer Day 2025 to inaugurate the Paris-Saclay Cancer Campus.
Main themes
Cancer research and treatment, Paris-Saclay Cancer Campus (PSCC), Gustave Roussy Institute, ten-year national cancer strategy, public health and prevention, research funding and investment, anti-tobacco programs, rising cancer prevalence, clinical and research collaboration, philanthropy and private partnerships, France 2030 innovation strategy
Duration
~31 min
83rd percentile
Words
3,704
83rd percentile
Sentences
151
81st percentile
Readability
57
82nd percentile
Grade
11.3
36th percentile
Syntax
3.19
71st percentile
Vocabulary
1.99
9th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 33%32%
  • Ceremonial 22%22%
  • Economic 21%21%
  • Institutional 14%14%
  • Technological 9%9%
  • Environmental 1%1%
  • Geopolitical 0%0%
  • Not in focus 1%

151 sentences in 29 paragraphs

So, ladies and gentlemen ministers, ladies and gentlemen, in your ranks and qualities.

This way, we are sure not to forget anyone and to get straight to the point. I wanted to first really express how happy I am to be among you with my wife today. And thank you, Mr. Mayor, for welcoming us to your municipality. And I thank all the elected officials from the area who are here; this is an important step.

I wanted to say a few words about the fight against cancer, about Gustave Roussy, and the ambitions we have in terms of health and research today. Indeed, we are gathered together for a somewhat special day, which is World Cancer Day, in this center, which is not a coincidence, that is the first in France, in Europe, and the fourth in the world, and which aims, as I understood everything that was explained to me this morning, to become the first.

So, I really wanted to first thank you for your commitment. And I think that over the last few decades, we have built on a French model that was invented, that of cancer centers, which has indeed managed to invent flexibilities, if I may say so, in organization, in a link between clinical practice and research, with successive ambitions that have multiplied. And I want to truly thank all the researchers, caregivers, and all the staff who are engaged in the fight against cancer, but also the companies, of course, all the companies in the sector that contribute, and all the philanthropy that associates itself with this fight. And I want to reiterate my great admiration for all those who lead this battle.

Four years ago, we announced here a ten-year strategy to fight cancer. Several of you contributed to its conception. And by the way, I believe that Norbert IFRAH himself is currently leading a consultation this morning, which is why he is not with us, but it shows that this is a daily battle that requires a lot of commitment. And so, for the first time, we decided to move from a five-year strategy to a ten-year one. That was your proposal, and I believe it was truly the right one, to have visibility. The State, in addition to everything else, has dedicated 1.7 billion euros to it, which was a 20% increase compared to the previous cancer plan. And all of this, the ministers are here to confirm, is well consolidated, stabilized, whatever you may hear, visibility and stability of these funding.

We will take stock in the summer of this national strategy, which already has very good results with anti-tobacco programs, improved prevention, etc., but also a public health phenomenon that several of you have described in recent weeks and months, which is extremely concerning, but where we indeed see certain cancers that are not simply reappearing, but whose numbers are increasing, whose prevalence is rising very strongly in the population, and I believe we need to tackle this during the progress report we will have in the summer of our ten-year plan. This is about the fight against cancer, which is truly an objective for us in terms of essential public health research.

So in this context, we have a flagship project, if I may say so, that is in your territory, here. And I wanted to revisit, and this is the occasion of this day, the Paris-Saclay-Cancer Campus project, this PSCC, which we formally inaugurated today, but which was also launched several years ago, which was matured, which we announced here in 2021, but which had its first foundations five years ago, and which was also one of the key points of the Innovation 2030 strategy that we were able to announce.

So, I really want to thank all those who have allowed this PSCC to advance and to express my gratitude and trust to them. First, of course, the IGR, its caregivers, all of its teams. Professor, I really want to thank you for accepting to leave your more southern lands to come to Paris, and I have a thought for Professor SORIA who preceded you. Here is a harmonious succession, and thank you to Professor BARLESI, to all his teams, to the research teams, medical teams, in short, to all those who surround me today and are here, to whom we owe a lot, but also to all the caregivers I was able to meet throughout the morning. I obviously thank all the partners, Inserm, Didier, thank you, Sanofi, the Polytechnic Institute, the University of Paris-Saclay, INCa, UniCancer. All the private partners and foundations as well, and thank you immensely to philanthropy. I want to thank all the elected officials from the area who have supported this project, the city, the territory, the department, and the president of the region has also confirmed her commitment to us. The regional prefecture and the departmental prefecture and all the state services, and France 2030, and obviously all the ministries that have been involved, foremost among them the Ministry of Health and the Ministry of Research.

What is being done here, I said, is French and European excellence. And fundamentally, what we want to enable you to do is to accelerate and multiply it. The PSCC is at the heart of both our cancer fight plan and everything we are doing with France 2030 in terms of innovation. A few months ago, I announced in this context our major projects within the framework of Health France 2030 with four thematic bioclusters in addition to this one, and so we will have the opportunity shortly to take stock with all of its leaders, but from Paris, Lyon, Évry-Courcouronnes, Marseille, and obviously right here, we have a Health Innovation 2030 plan that is being deployed.

This also includes funding for three of them over ten years amounting to about 10 million per year, in addition to all the recurring funding and the partners involved. For two of them, we are in the process of securing five-year funding. There you go, we are in the process of bringing them up. And all of this has been added to the IHUs that preexisted and that have, in a way, initiated this entire movement that we will continue.

And in total, France 2030 is deploying more than 7 billion euros to make France a leader in health innovation and to meet the major challenges. And so, I want to tell you here that this is an important step with this inauguration, but we will continue to go faster and stronger. First, to help you consolidate all the work done in terms of prevention, which I will explain in a moment, but which is an important innovation and which will be conducted here in terms of ultra-rapid diagnostics, obviously in terms of treatment, clinical trials, and support, but also in terms of research. You will double your capacities on the campus and allow, as we have done in recent years, to attract the best research teams in all fields and with the greatest interdisciplinarity, and to do so, there too, with public teams and with private contributions.

So, fundamentally, what did I hear this morning and what did I want to tell you for the future, beyond these words that were prepared for me? First, I think that, whatever we may hear and say, we have in France an immense chance to have the health system that is ours, and it is a strength. And this health system, whether public or private, and particularly our hospitals, our cancer centers, we know, in recent years, have undergone many shocks, have suffered a lot, and I really want to reiterate my gratitude to all the staff, but with the Ma santé 2022 plan launched as early as 2018, what was done during COVID, then the post-COVID plan with the various successive Ségur reforms and reorganizations, I believe, allows us to return to the right path. We are not there yet because there is a lot of work to do, but there has been an investment in people, and it needs to be consolidated. And I want to say here, because I heard a lot of concern this morning, so I take this opportunity to dispel a few rumors, no, we are not going to re-tax the overtime of caregivers, no way. And yes, the bonuses that were given in the Ségur are indeed permanent bonuses that are integrated into the salary, including in the CLCs. I prefer to say it because it always creates anxiety for people who work a lot. On the other hand, what we want to do is continue to reform our hospitals, our CLCs, because we also need to reform our collective organization. And there, I must say that cancer centers are a good model for public hospitals because they provide more flexibility in organization, they place the medical aspect more at the heart of management, where we have perhaps, in hospitals, sometimes too dehumanized and bureaucratized, to use an awful word, in any case, put too many administrative tasks in the management of care. So we will continue this, but it is a treasure.

Next, to succeed in what we are doing, the link between clinical practice and research is key. You all told me this morning. It is what is embodied in the IGR model and what is carried in all our centers of excellence, and I want us to really consolidate it in the French model. Three, as you perfectly described, what works is breaking down barriers. And I believe that sometimes one of the small weaknesses we have in France is that we have corporatism, we have compartmentalization. And so, we need to succeed in pushing these walls. That is what you are doing here. Breaking down barriers between disciplines. I believe that the success of your model, and what you want to do to go even faster, is to break down barriers between, of course, oncology, but all other medical disciplines, between imaging, biology, clinical practice, to be able to do so also with environmental sciences, which are crucial, as I was explained before, to explain etiology and succeed in better preventing cancers, obviously genetics. And so, the breaking down of disciplines is key. And that is what the cluster effect allows, and that is what, right here, the project we have collectively supported will allow, because with the unity of place, it brings together researchers, caregivers, scientists, who come from these different disciplines and who are united with a common goal. The second breaking down is between public and private. A long-standing battle in our country, but I believe in this "at the same time." I have always believed in it, I do not change my mind much, that is to say that we need more money. We have put in more public money, and it will be consolidated despite the budgetary debates we hear.

You heard me, I confirmed the figures, both from the cancer plan, what we are putting into the IGR, and what we will put into these major projects. But if we want to scale up to our major competitors, we need to attract the champions that you are, and we need to mobilize private money, because that is what all our major competitors do. When we talk about the figures of major universities, major research centers in Asia and the United States, they mobilize private money. And so it is a good thing, by defining the right ethical rules and intellectual property, and therefore the framework, to have groups like Sanofi involved here, wonderful companies like Owkin coming back to get involved, and to be able to develop even more broadly, since you have done it with GSK and you will do it with other partners, pharma, companies. And to also allow philanthropy to get involved. I really thank the foundations, the philanthropists who have supported the project, these innovations, who have also helped finance chairs of excellence or bring back the best researchers. And so this public-private breaking down, we will continue to do because it is good and necessary for the country. And that is also why when I hear people, in our public debates, saying: "it's great, we need to invest more in health, we need to invest more in research, but really, we need to massacre as much as we can of entrepreneurship, we need to tax these companies much more," I tell them: You have two threads that touch. Because it is not true that we will do everything.

First, you can only take money from what you create, and secondly, you would rather want to bring back people who will create value here, so that they multiply it. That is what we are doing here. It is the best example that the "at the same time" works and that, yes, we need to have people who are champions in their field. We need to have people who are much better paid because they are champions and it is a competitive market. And we need to have companies that come to do it here.

And so, if we want to respond to your three criteria from earlier, money, money, money, that is what Professor BARLESI told me. I asked him: what are the three things that block you? "Money, money, money." So we will continue to put on the plan what we have set for ourselves, but we need to mobilize even more private partners to engage in collaborative research, to finance finalized projects with researchers from Inserm, the university, the hospital, the cluster. And we need to encourage even more companies, philanthropists to come and finance these projects, finance chairs, finance excellence in terms of research and in terms of care. So breaking down silos, funding, and thus public-private collaboration. And then, I wanted to tell you that to go further, we will try to accelerate together on a few elements that may seem simple but are key: data. You presented it perfectly. I believe we need to be clear-eyed.

There is a huge amount of work that you are doing here that is remarkable. There is the work we are doing with PariSanté Campus, with the Health Data Hub. But I believe that honesty compels me to say that we have not fully explored this area. We are still far too slow, and we are often slow even between the administrative structures themselves. And I believe we need to arrive at a point, and I ask that the ministers propose to me by spring, very simple evolutions, but we must distinguish the proper protection of personal data, the fact that we do not want these personal data to be used for adverse selection purposes, for example in insurance systems, but a much simpler use so that they can be mobilized by research, and particularly by units like yours, because that is what will allow breakthroughs to happen much more quickly.

So, we have treasure troves of data from CNAM to Inserm, passing through our hospitals. We have a rather centralized system. We have set up units. We need to move much faster. So simplifying the French and European framework, but already French, for the use of data and everything we can do even without the law, we will do it very quickly. The second thing is our clinical trials. I cannot continue to hear. We improved things a lot at one point. We had our fast-tracks, 2017-2020. We did, and I really thank ANSM, the Haute Autorité de Santé, our ARS, who did remarkable work during COVID, we broke all the deadlines.

We have somewhat reverted to the way things were before. So, we cannot say that we have clinical trials being conducted in Spain or Germany, just for administrative reasons. That is madness. And so, in the same way, I want us to correct that and align ourselves with the best in Europe. It is not complicated; we are normally all in the same system, or even trying to do better, because it is a competitive element for our system. And we cannot attract the big pharma companies, I speak under the control of those present, or the most innovative companies, if we tell them here: "We will not allow you to conduct your phase 1 trial," or "It will take three or four times longer than in Barcelona, where it is already authorized." And so we must break these delays and thus move much faster on clinical trials.

And then the third thing is artificial intelligence. Several of you are involved in this. France will host the summit for action on artificial intelligence, which is truly an international summit where we will have heads of state, government leaders, investors, and companies. If there is one area where AI will allow, and is already revolutionizing things, it is yours.

And so I want us to be the best in this area as well. And so what does that imply we do? 1) We train talents in France. That is also the strength of our system and it will be the connection between our ecosystems. We probably have one of the best global clusters in terms of training and AI talent, which is Saclay. And so the connections are massive. And so, that is an opportunity. We will develop during the summit new chairs of excellence, new training programs to train more, to bring back researchers and data scientists, mathematicians.

2) We have controllable, decarbonized energy, and we overproduce. We always forget to mention it, but France exported 90 TWh of energy last year. It is nuclear, meaning it is decarbonized. We are exporting it to our European neighbors, which is wonderful, but that is the most rare element today on the planet to attract those famous data centers and the computing capacities for AI models and storage. And well, on the occasion of the summit, we will try to mobilize international funding and actors to create these capacities in France and thus enable you to have computing capacities that will accelerate your research, including in health.

And then 3) we need to accelerate synergies; it is interdisciplinarity. And so, it is the circulation of talents between INSERM, INRIA, CEA, CNRS, real funding agencies that must lead research with ANR, I also want to thank France 2030, and then clusters with finalized research. So AI relies on a research and care ecosystem like yours; it will create opportunities, it is hopes for life expectancy and treatments, it is a gain of chances for patients, it is years of research saved for researchers, it is a change in working conditions for caregivers.

So I truly want us to put this AI action summit at the service of medicine, of research in life sciences, and that will be the goal for next week. I mentioned Owkin earlier, which is one of the champions in this field, but we will continue to move forward in this direction. And count on me to make AI in health one of the levers for acceleration. There you go, I do not want to be longer, but you see how revolutionary this campus around the IGR is. And I really want to thank all those in the territory who have contributed to making these first steps possible, and to tell you that you can be proud because you have here the flagship of what is already a European champion, but what will be a world champion. I commit to this here because we will succeed. And it is also what will allow us to drive the real transformation of the medical model that we must achieve in our country.

We have a model that was conceived several decades ago, fundamentally in the mid-1960s, and it was a great opportunity, but it was designed for a population that did not live so long and had serious diseases that needed to be treated at the end of the chain, so to speak, with a system that was well integrated across the territory. And we have become, and it is a chance, in a few decades, a population that lives much longer and where there are more and more chronic diseases, where we have precisely cancers to prevent and manage.

We must pivot our health system so that it is more preventive, more individualized, and that it allows us to manage an increasing number of chronic diseases, and to do so at the best cost, while continuing to maintain the synergy between clinical practice and research. Said like that, it seems simple. It is a very difficult thing to pivot a system. And for all those who are in organizations, you know it. What we are doing here is a tremendous accelerator of this change because you are carrying a much more preventive, much more personalized medicine, and that also allows for revolutions and efficiency gains, and I say this also for all those who hear the figures and sometimes stated in remarks like today, it is an investment that also allows for a lot of savings, everything we are discussing. Because if we better prevent cancer, if we enable better monitoring and support, we avoid losses of chances, we avoid a lot of unnecessary treatments, we avoid very serious situations that cost much more.

So, you see that here, you are at the heart of a territory, at the heart of excellence in the fight against cancer, at the heart of France 2030 and health innovation and everything that encompasses it, but also of the transformation of our national model. Thank you to all those who carry it and to all the teams in the administration, our architects, the philanthropists, the private sector teams who have made this project possible and who will now continue this decade; it will be a true revolution.

Thank you, professors, and thank you to all the teams around you who are here, researchers, caregivers, administrators, health professionals, I am infinitely proud to be by your side and just to help you succeed.

Long live the Republic and long live France.